Stapokibart Was Granted Marketing Approval From National Medical Products Administration For The Treatment Of Moderate-to-severe Atopic Dermatitis in Adults
CHENGDU, China, Sept. 13, 2024 /PRNewswire/ — Keymed Biosciences Inc. (HKEX: 02162) today announced the National Medical Products Administration (the “NMPA”) of China has recently approved the new drug applicati… อ่านเพิ่ม